Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery

American Journal of Ophthalmology

Volumn 149, Issue 6, 2010, Pages

  Galor, Anat ^a   Yoo, Sonia H ^a   Piccoli, Fernanda V R ^a   Schmitt, Artur J ^a   Chang, Victoria ^a   Perez, Victor L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN GLUE; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; AUTOGRAFT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA SURGERY; DRUG SAFETY; DRUG TOLERABILITY; ESTHETICS; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; MALE; OPEN STUDY; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SLIT LAMP; SUTURING METHOD; TREATMENT RESPONSE; VISUAL ACUITY; WOUND DEHISCENCE;

EID: 77952543569     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.01.015     Document Type: Article

References (25)

1. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
2. Pieramici D.J., Rabena M., Castellarin A.A., et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 115 (2008) e47-e54
3. Regillo C.D., Brown D.M., Abraham P., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008) 239-248
4. Faghihi H., Roohipoor R., Mohammadi S.F., et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 18 (2008) 941-948
5. Arevalo J.F., Garcia-Amaris R.A., Roca J.A., et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 33 (2007) 2098-2105
6. Arevalo J.F., Sanchez J.G., Fromow-Guerra J., et al., Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 247 6 (2009) 735-743
7. Bock F., Konig Y., Kruse F., Baier M., and Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246 (2008) 281-284
8. DeStafeno J.J., and Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125 (2007) 834-836
9. Kim S.W., Ha B.J., Kim E.K., Tchah H., and Kim T.I. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115 (2008) e33-e38
10. Uy H.S., Chan P.S., and Ang R.E. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 27 (2008) 70-73
11. Mackenzie S.E., Tucker W.R., and Poole T.R. Bevacizumab (avastin) for corneal neovascularization-corneal light shield soaked application. Cornea 28 (2009) 246-247
12. Doctor P.P., Bhat P.V., and Foster C.S. Subconjunctival bevacizumab for corneal neovascularization. Cornea 27 (2008) 992-995
13. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 27 (2008) 1195-1199
14. Bahar I., Kaiserman I., McAllum P., Rootman D., and Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27 (2008) 142-147
15. Wu P.C., Kuo H.K., Tai M.H., and Shin S.J. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28 (2009) 103-104
16. Bahar I., Kaiserman I., McAllum P., Rootman D., and Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33 (2008) 23-28
17. Coroneo M.T., Di Girolamo N., and Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 10 (1999) 282-288
18. Chui J., Di Girolamo N., Wakefield D., and Coroneo M.T. The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf 6 (2008) 24-43
19. Jin J., Guan M., Sima J., et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22 (2003) 473-477
20. Lee D.H., Cho H.J., Kim J.T., Choi J.S., and Joo C.K. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20 (2001) 738-742
21. Lee J.K., Song Y.S., Ha H.S., et al. Endothelial progenitor cells in pterygium pathogenesis. Eye 21 (2007) 1186-1193
22. Prabhasawat P., Barton K., Burkett G., and Tseng S.C. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology 104 (1997) 974-985
23. Galor A., and Yoo S.H. Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging (2010) Forthcoming
24. Genentech Inc. Lucentis package insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf Accessed February 15, 2010
25. Genentech Inc. Avastin package insert. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf Accessed February 15, 2010